This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idenix Pharma Buyout Likely: Survey

Stocks in this article: INHX IDIX ACHN GILD BMY

NEW YORK ( TheStreet) -- Wall Street investors remain bullish on hepatitis C drug stocks and by a wide margin believe Idenix Pharmaceuticals (IDIX) will be acquired.

ISI Group biotech analyst Mark Schoenebaum held a lunch meeting Friday for 120 investors to discuss the current state of hepatitis C drug development. As part of his meeting, Schoenebaum surveyed his investor audience -- made up of 30% generalists, 20% arbs and 30% specialists -- on their views and opinions about the current red-hot topics in hepatitis C.

Asked if Idenix Pharma has a greater than 50% chance of being acquired, 79% of the investors responded in the affirmative, 21% said no.

The group was more evenly split on Achillion Pharmaceuticals' (ACHN) chances for a takeout, with 49% leaning yes and 51% saying no.

Gilead Science's (GILD) $11 billion acquisition of Pharmasset was the spark that ignited the recent run in Hep C drug stocks. Schoenebaum's buy-side investor crowd likes the blockbuster deal, with 64% predicting Gilead will create value with its purchase of Pharmasset. Thirty-six percent say Gilead is going to destroy shareholder value with this deal.

On a related note, 61% say Gilead shares are a buy today. Gilead shares rose 3 cents to $47.24 Friday and the stock is up about 16% for the year, leading all of the large-cap biotechs. Thirty-nine percent of Schoenebaum's respondents say Gilead is a sell at these levels.

Bristol-Myer Squibb's (BMY) $2.5 billion purchase of Inhibitex (INHX) is also viewed favorably by a wide margin, although a small majority (54%) of investors view Bristol as a sell at current valuation.

The size of the commercial opportunity for new all-oral Hep C treatment regimens is a much-debated topic these days. The investors at today's meeting generally fall into the bull camp, with 48% predicting worldwide Hep C drug sales between $8 billion and $10 billion by 2019.

Idenix shares neared Friday's close down 6% to $13.94 while Achillion was off 11.5% to $9.39.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs